A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer
Status:
Withdrawn
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the preliminary efficacy of KA2507 (an orally active potent and selective HDAC6
inhibitor) in patients with advanced biliary tract cancer (BTC) previously treated with
standard of care chemotherapy.